Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

By D. Catovsky, S. Richards, E. Matutes, D. Oscier, M. Dyer, Rf Bezares, A. Pettitt, T. Hamblin, D. Milligan, J. Child and 9 more. The Lancet, 2007

705 citations recorded by the source corpus.

Subfields: Genetics, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/c5843834250b792561f9df6b5819595517530787

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Ralf Küppers
2. D. Calado

In Pathology and Forensic Medicine

1. M. Hallek
2. Ralf Küppers
3. D. Calado

Citations in the corpus

• From pathogenesis to treatment of chronic lymphocytic leukaemia (2010, background): “The role of IGHV mutation status in guiding therapy is currently unresolved and treatment decisions should not be based on it outside of clinical trial”
• TP53 mutation and survival in chronic lymphocytic leukemia. (2010, methodology): “However, in contrast to our study, follow-up was relatively short, and unconfirmed mutations were grouped together with true mutations; these factors make interpretation difficult.6 Although our findings clearly show a strong association between poor clinical outcome and TP53 mutation, the findings ”